HeartSciences Other Long-Term Assets 2022-2025 | HSCS
HeartSciences other long-term assets from 2022 to 2025. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
| HeartSciences Annual Other Long-Term Assets (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
| 2021 | $0 |
| HeartSciences Quarterly Other Long-Term Assets (Millions of US $) |
|
|---|---|
| 2025-01-31 | |
| 2024-10-31 | |
| 2024-07-31 | |
| 2024-04-30 | |
| 2024-01-31 | |
| 2023-10-31 | |
| 2023-07-31 | |
| 2023-04-30 | |
| 2023-01-31 | |
| 2022-10-31 | |
| 2022-07-31 | |
| 2022-04-30 | |
| 2022-01-31 | |
| 2021-10-31 | |
| 2021-07-31 | |
| 2021-04-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.004B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $45.674B | 58.11 |
| Tempus AI (TEM) | United States | $11.334B | 0.00 |
| Doximity (DOCS) | United States | $11.302B | 52.32 |
| Hims & Hers Health (HIMS) | United States | $9.269B | 96.30 |
| IRhythm Technologies (IRTC) | United States | $4.836B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $3.893B | 60.83 |
| Hinge Health (HNGE) | United States | $3.474B | 0.00 |
| Privia Health (PRVA) | United States | $2.652B | 181.25 |
| Enovis (ENOV) | United States | $1.835B | 10.23 |
| Phreesia (PHR) | United States | $1.643B | 0.00 |
| Schrodinger (SDGR) | United States | $1.509B | 0.00 |
| 10x Genomics (TXG) | United States | $1.436B | 0.00 |
| Azenta (AZTA) | United States | $1.397B | 64.92 |
| Clover Health Investments (CLOV) | United States | $1.394B | 0.00 |
| Omnicell (OMCL) | United States | $1.346B | 23.75 |
| Evolent Health (EVH) | United States | $1.257B | 107.10 |
| Claritev (CTEV) | United States | $0.687B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.596B | 0.00 |
| Veradigm (MDRX) | United States | $0.487B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.487B | 0.00 |
| Standard BioTools (LAB) | United States | $0.475B | 0.00 |
| Talkspace (TALK) | United States | $0.452B | 135.00 |
| Outset Medical (OM) | United States | $0.347B | 0.00 |
| TruBridge (TBRG) | United States | $0.343B | 762.00 |
| Nyxoah SA (NYXH) | Belgium | $0.265B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.262B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.211B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.157B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.136B | 0.00 |
| American Well (AMWL) | United States | $0.116B | 0.00 |
| CareCloud (CCLD) | United States | $0.107B | 4.06 |
| Pulmonx (LUNG) | United States | $0.106B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.105B | 0.00 |
| 111 (YI) | China | $0.067B | 0.00 |
| HeartBeam (BEAT) | United States | $0.048B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.044B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.043B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.037B | 0.00 |
| Zhongchao (ZCMD) | China | $0.031B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.023B | 0.00 |
| Precipio (PRPO) | United States | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.015B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.013B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.011B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.010B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.008B | 0.00 |
| Movano (MOVE) | United States | $0.005B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |